FOSCARNET PACKAGE INSERT PDF

Name of the medicinal product. Foscavir 24 mg/ml Solution for Infusion. 2. Qualitative and quantitative composition. Foscarnet trisodium hexahydrate 24 mg /ml. Package leaflet: Information for the user. Foscavir®. 24 mg/ml Solution for Infusion foscarnet. M UK. Read all of this leaflet carefully before you start. Foscavir™ (Foscarnet Sodium) Injection Product Insert rubber latex has not been used in the manufacture of this device or drug container closure system.

Author: Gokinos Tarr
Country: Venezuela
Language: English (Spanish)
Genre: Sex
Published (Last): 23 August 2008
Pages: 216
PDF File Size: 11.21 Mb
ePub File Size: 14.9 Mb
ISBN: 495-9-13622-212-4
Downloads: 88601
Price: Free* [*Free Regsitration Required]
Uploader: Nikogore

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as degarelix. Clarithromycin is also associated with an established risk for QT prolongation and TdP. Uptake of foscarnet into the bone matrix is likely due to its structural similarity to phosphate.

Major Avoid coadministration of ribociclib with foscarnet due to an increased risk for QT prolongation and torsade de pointes TdP. Quinine has also been associated with QT prolongation and rare cases of TdP.

Major There may be an increased risk for QT prolongation and torsade de pointes TdP during concurrent use of fluvoxamine and foscarnet. Foscarnet is not metabolized in the liver. Malaise, oedema, chest pain dinjection site pain, injection site inflammation.

Major Avoid coadministration of foscarnet with tamoxifen due to foscagnet risk of QT prolongation. Clear and colourless solution.

However, diluted solutions should be refrigerated and storage restricted to 24 hours. Asenapine has also been associated with QT prolongation.

  AISBERG UL NOSTRU SE TOPESTE PDF

Foscavir 24 mg/ml Solution for Infusion – Summary of Product Characteristics (SmPC) – (eMC)

Moreover, since Foscavir can reduce serum levels of ionised calcium, extreme caution is advised when used concurrently with other drugs known to influence serum calcium levels, like i.

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as quinidine. Animal data show that deposition is greater in young animals. Citalopram causes dose-dependent QT interval prolongation. In addition, there are postmarketing reports of TdP with trazodone. This information is intended for use by health professionals.

Foscavir (foscarnet sodium) dose, indications, adverse effects, interactions from

Pasireotide may also prolong the QT interval. Although extremely rare, TdP has been reported during postmarketing surveillance of ofloxacin. Also, the risk of renal toxicity may be increased if foscarnet is used in conjunction with other nephrotoxic agents such as lithium. Major Avoid concurrent administration of macimorelin with drugs that prolong the QT interval, such as foscarnet. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as telithromycin.

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as tolterodine.

Both QT prolongation and torsade de pointes TdP have been reported during postmarketing use of foscarnet. The safety of foscarnet in pregnancy has not been established, so it should be used only when clearly needed. Cases of long QT syndrome and TdP packge have been described with maprotiline use, but rarely occur when the drug is used alone in normal prescribed doses and insrrt the absence of other known risk factors for QT prolongation. Ibutilide administration can also cause QT prolongation and TdP; proarrhythmic events should be anticipated.

  CONFIGURATION ROUTAGE STATIQUE CISCO PDF

Eribulin has also been associated with QT prolongation. Since bradycardia is a risk factor for development of TdP, the potential occurrence pakage bradycardia during octreotide administration could theoretically increase the risk of TdP in patients receiving drugs that prolong the QT interval.

Foscavir 24 mg/ml Solution for Infusion

Moderate Avoid concurrent use of loop diuretics with foscarnet. Back to top Clinigen Healthcare Ltd contact details. Active ingredient foscarnet trisodium hexahydrate.

Foscarnet sodium has been demonstrated to adversely affect development of tooth enamel in mice and rats. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as disopyramide.

Bismuth Subcitrate Potassium; Metronidazole; Tetracycline: Therefore, patients must be carefully monitored for such electrolyte imbalances and potential sequelae. Packag that decrease renal function may also increase concentrations of tenofovir.

Obtain an electrocardiogram and electrolyte concentrations at baseline and periodically during treatment. Lithium has also been associated with QT prolongation. Ensure policies and procedures for managing abnormalities such as tetany, seizures, and imsert disturbances are in place prior to administering foscarnet.